CD133 is recognized as a CSC marker in brain, colon, melanoma, bone sarcomas, non-small cell lung cancer, and other solid tumors (5,6,13–16), but this notion was challenged by studies from other groups. This evidence concerns the gene PROM1 and bone sarcoma.